Loading
Life sciences · Journal article
Microorganisms · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Newcastle disease virus (NDV) is a promising oncolytic virus, but tumor heterogeneity constrains its clinical translation. The key determinants driving variable NDV oncolytic potency amid tumor heterogeneity remain incompletely elucidated. The main scope of this study included analyzing 22 human cancer cell lines representing 11 tumor types and identifying five gene co-expression modules associated with NDV susceptibility through weighted gene co-expression network analysis. Integrative multi-omics analyses of NDV-infected HCT116 cells, the least-susceptible cell line in our panel, predicted metabolic processes, innate immune defenses, and multiple forms of cell death as candidate pathways modulating NDV oncolytic efficacy. These key bioinformatic findings were further validated by genome-wide CRISPR-Cas9 screening, which uncovered POLR2G and SREBF1 as central components of the pro-oncolytic network and TNFRSF1A, TNFAIP3, and CASP9 as core mediators of the anti-oncolytic network. Their functional roles were further verified via genetic manipulation and pharmacological perturbation of JAK-STAT, TLR4, and apoptotic signaling. In conclusion, our findings support a bidirectional model wherein host metabolic programs promote NDV replication and oncolysis, whereas antiviral-innate immune signaling restricts them, providing candidate targets for host-directed combination therapy amid tumor heterogeneity.